BR112013000779A2 - composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial - Google Patents
composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelialInfo
- Publication number
- BR112013000779A2 BR112013000779A2 BR112013000779A BR112013000779A BR112013000779A2 BR 112013000779 A2 BR112013000779 A2 BR 112013000779A2 BR 112013000779 A BR112013000779 A BR 112013000779A BR 112013000779 A BR112013000779 A BR 112013000779A BR 112013000779 A2 BR112013000779 A2 BR 112013000779A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- potentiated form
- activated potentiated
- angiotensin
- receptor
- Prior art date
Links
- 230000003511 endothelial effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 102000008873 Angiotensin II receptor Human genes 0.000 title 1
- 108050000824 Angiotensin II receptor Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endogena biológica, composição farmacêutica e uso de combinação de molécula biológica endogena com forma ativada potenciada de anticorpo para a sintase no endotelial. a presente invenção proporciona um método de aumentar o efeito de uma forma ativada potenciada de um anticorpo para uma molécula endógena biológica combinando a referida molécula biológica endógena com uma forma ativada potenciada de um anticorpo para a sintase no endotelial. a presente invenção também proporciona uma composição farmacêutica que compreende a) uma forma ativada potenciada de um anticorpo para uma molécula endógena biológica e b) uma forma ativada potenciada de um anticorpo para a sintase no.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010129291/15A RU2525156C2 (ru) | 2010-07-15 | 2010-07-15 | Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии |
| RU2010129292/15A RU2523557C2 (ru) | 2010-07-15 | 2010-07-15 | Способ лечения вегетососудистой дистонии и фармацевтическая композиция для лечения вегетососудистой дистонии |
| RU2010129290/15A RU2525155C2 (ru) | 2010-07-15 | 2010-07-15 | Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для комплексной терапии хронической сердечной недостаточности |
| RU2011110106/15A RU2523451C2 (ru) | 2011-03-17 | 2011-03-17 | Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для лечения хронической сердечной недостаточности |
| PCT/IB2011/002391 WO2012007846A2 (en) | 2010-07-15 | 2011-07-15 | A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013000779A2 true BR112013000779A2 (pt) | 2016-06-07 |
Family
ID=44899163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013000779A BR112013000779A2 (pt) | 2010-07-15 | 2011-07-15 | composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8703124B2 (pt) |
| EP (1) | EP2593482A2 (pt) |
| JP (1) | JP2013532183A (pt) |
| KR (1) | KR20140009110A (pt) |
| AR (1) | AR084707A1 (pt) |
| AU (1) | AU2011278039B2 (pt) |
| BR (1) | BR112013000779A2 (pt) |
| CA (1) | CA2804969A1 (pt) |
| DE (1) | DE112011102356T5 (pt) |
| DK (1) | DK201370080A (pt) |
| EA (1) | EA201300128A1 (pt) |
| EE (1) | EE201300004A (pt) |
| FR (1) | FR2962654A1 (pt) |
| GB (1) | GB2496795A (pt) |
| IT (1) | ITTO20110640A1 (pt) |
| MX (1) | MX2013000544A (pt) |
| NO (1) | NO20130217A1 (pt) |
| SE (1) | SE1350177A1 (pt) |
| SG (1) | SG187034A1 (pt) |
| UA (1) | UA114699C2 (pt) |
| WO (1) | WO2012007846A2 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2201255C1 (ru) * | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции сосудистого тонуса |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| SG10201505561TA (en) | 2010-07-15 | 2015-08-28 | Oleg Iliich Epshtein | A Method Of Increasing The Effect Of An Activated-Potentiated Form Of An Antibody |
| DE112011102362T5 (de) | 2010-07-15 | 2013-04-25 | Oleg Iliich Epshtein | Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen |
| EA029199B1 (ru) | 2010-07-21 | 2018-02-28 | Олег Ильич Эпштейн | Комбинированная фармацевтическая композиция для лечения синдрома дефицита внимания и гиперактивности и способы лечения синдрома дефицита внимания и гиперактивности |
| RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311897A (en) | 1979-08-28 | 1982-01-19 | Union Carbide Corporation | Plasma arc torch and nozzle assembly |
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2201255C1 (ru) * | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции сосудистого тонуса |
| UA76641C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| UA76639C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
| CN101107003B (zh) | 2003-03-14 | 2012-08-08 | 营养学研究有限公司 | 用于治疗疼痛和/或炎症的顺势疗法的配剂 |
| JP5239899B2 (ja) | 2008-07-29 | 2013-07-17 | 株式会社リコー | 画像形成装置 |
-
2011
- 2011-07-15 SG SG2013002282A patent/SG187034A1/en unknown
- 2011-07-15 US US13/135,882 patent/US8703124B2/en not_active Expired - Fee Related
- 2011-07-15 CA CA2804969A patent/CA2804969A1/en not_active Abandoned
- 2011-07-15 AU AU2011278039A patent/AU2011278039B2/en not_active Ceased
- 2011-07-15 DE DE112011102356T patent/DE112011102356T5/de not_active Withdrawn
- 2011-07-15 JP JP2013519177A patent/JP2013532183A/ja not_active Withdrawn
- 2011-07-15 EA EA201300128A patent/EA201300128A1/ru unknown
- 2011-07-15 BR BR112013000779A patent/BR112013000779A2/pt not_active IP Right Cessation
- 2011-07-15 IT IT000640A patent/ITTO20110640A1/it unknown
- 2011-07-15 WO PCT/IB2011/002391 patent/WO2012007846A2/en active Application Filing
- 2011-07-15 GB GB1302656.2A patent/GB2496795A/en not_active Withdrawn
- 2011-07-15 UA UAA201300107A patent/UA114699C2/uk unknown
- 2011-07-15 EE EEP201300004A patent/EE201300004A/xx unknown
- 2011-07-15 KR KR1020137003520A patent/KR20140009110A/ko not_active Application Discontinuation
- 2011-07-15 MX MX2013000544A patent/MX2013000544A/es unknown
- 2011-07-15 SE SE1350177A patent/SE1350177A1/sv not_active Application Discontinuation
- 2011-07-15 EP EP11779851.2A patent/EP2593482A2/en not_active Ceased
- 2011-07-15 FR FR1156474A patent/FR2962654A1/fr not_active Withdrawn
- 2011-07-18 AR ARP110102577A patent/AR084707A1/es unknown
-
2013
- 2013-02-08 NO NO20130217A patent/NO20130217A1/no not_active Application Discontinuation
- 2013-02-14 DK DKPA201370080A patent/DK201370080A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011278039B2 (en) | 2015-07-23 |
| NO20130217A1 (no) | 2013-03-22 |
| GB2496795A (en) | 2013-05-22 |
| WO2012007846A3 (en) | 2012-04-12 |
| ITTO20110640A1 (it) | 2012-01-16 |
| US8703124B2 (en) | 2014-04-22 |
| EP2593482A2 (en) | 2013-05-22 |
| AR084707A1 (es) | 2013-06-05 |
| SG187034A1 (en) | 2013-02-28 |
| GB201302656D0 (en) | 2013-04-03 |
| AU2011278039A1 (en) | 2013-03-07 |
| EA201300128A1 (ru) | 2013-12-30 |
| KR20140009110A (ko) | 2014-01-22 |
| JP2013532183A (ja) | 2013-08-15 |
| US20120251584A1 (en) | 2012-10-04 |
| SE1350177A1 (sv) | 2013-04-12 |
| CA2804969A1 (en) | 2012-01-19 |
| WO2012007846A2 (en) | 2012-01-19 |
| MX2013000544A (es) | 2013-10-28 |
| EE201300004A (et) | 2013-08-15 |
| FR2962654A1 (fr) | 2012-01-20 |
| UA114699C2 (uk) | 2017-07-25 |
| DE112011102356T5 (de) | 2013-04-18 |
| DK201370080A (en) | 2013-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122278T1 (el) | Αντι il-36r αντισωματα | |
| CY1121843T1 (el) | Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου | |
| BR112013000779A2 (pt) | composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| CR20160206A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5 | |
| CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
| NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
| EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| CL2011002943A1 (es) | Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica. | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| EA201590590A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
| MY158560A (en) | Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof | |
| ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| ECSP11011297A (es) | Proteinas ligadoras il-17 | |
| ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
| GT201200189A (es) | Antagonistas de pcsk9 | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| TR201903026T4 (tr) | S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari. | |
| EA201291180A1 (ru) | Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) | |
| CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| BR112013000840A2 (pt) | método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial. | |
| BRPI0914410A2 (pt) | composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares. | |
| BR112015012708A2 (pt) | anticorpos para bmp-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B04C | Request for examination: application reinstated [chapter 4.3 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |